The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the matter.
Novartis's Sandoz is adding Aspen's Japan business in part to boost access to hospitals there.
Third-quarter core net income rose 17% at constant currencies to $3.2 billion.
The popular pain relief injection was banned in July 2018 for using an excipient called Transcutol-P that allegedly causes slow damage to the kidneys
Out-of-pocket payment for the treatment would vary as per insurance coverage, but the Swiss drugmaker will let insurers make payments over a five-year period - at $425,000 per year and will give partial rebates if it doesn't work.
One of the initiative Data 42, called as ‘moonshot’ project within Novartis, is trying to harness the power of data analytics, machine learning and AI to possibly find leads for new drugs, new patient approaches and identifying safety features, by wringing new insights out of old clinical trials data.
Emma Walmsley has taken bold and sensible steps, reshaping GSK to face up to a changed business environment.
The company's board has requested the nomination and remuneration committee to identify and recommend a suitable successor for the role
The Swiss group said in a statement there would be a net-loss of 1,000 jobs at different manufacturing facilities across the wealthy Alpine nation, in Basel, Schweizerhalle, Stein and Locarno.
According to an official release, Novartis Chief Executive Officer of Vas Narasimhan met Rao and discussed life sciences ecosystem in the state and the vision of the state government for the sector.
Joerg Reinhardt said "The review concluded that a spinoff would be in the best interests of Novartis shareholders."
Horlicks and Boost together are the leading malt based drinks in India with a 56 percent market share followed by Bournvita, Complan and others.
GSK said it will assess shareholding in its Indian subsidiary, GlaxoSmithKline Consumer hinting at a possible sale of the Indian unit.
Basel-based Novartis's offer of $41 per ordinary share and $82 per American depositary share represents a 47 percent premium to AAA's price before media reports on Sept. 27 that Novartis was interested.
Rajat Bose of rajatkbose.com recommends buying Novartis, Cipla, Bajaj Auto and Rain Industries.
All the medicines were tested in melanoma patients who had undergone surgery to cut out tumours and had a genetic mutation called BRAF, making them likely to respond to the targeted cancer pills. Patients with BRAF mutations constitute around half of the melanoma population.
Bringing you the latest news and updates.
Narasimhan will replace Joseph Jimenez, the incumbent CEO, who has informed the Board of Directors of his desire to step down in 2018, after eight years in position, the Basel-headquartered company said in a statement on Monday.
Jimenez is stepping down following a decade at Novartis after having successfully secured U.S. approval for a new gene therapy for leukemia last week but before Novartis returned to sales growth, which the company has forecast will resume in 2018.
The government's push for prescribing drugs by generic names could pose a further challenge.
Ilaris costs about USD 200,000 for a single year's treatment. Novartis makes around USD 250 million annually on the drug. But the new indication, if approved by the regulator, would expand the sales manifold,
Glenmark Pharmaceuticals, on Tuesday, said the US drug regulator cleared the company's investigational new drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar, which will assess its pharmacokinetics in comparison to Novartis anti-asthma biologic XOLAIR or omalizumab in healthy adult volunteers between 18-65 years of age.
As global drug makers are exiting low priority brands, their Indian counterparts are lapping up the opportunity buying established products at perhaps low valuations.
Intas said it is undertaking a detailed analysis on reports of inflammation and has advised doctors to avoid using the product, meant to treat an age-related eye condition, from this specific batch.
Tobramycin inhalation had US sales of USD 133.6 million as on December 2016 according to IMS data.